Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15643139 | 0.89 | KMT2A (0.36) | KMT2AATMMGLLACE | |
| SCHEMBL17929270 | 0.88 | MMP1 (0.32) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL17173818 | 0.88 | KMT2A (0.32) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL17155176 | 0.87 | MAPK1 (0.35) | KMT2AATMMGLLACE | |
| SCHEMBL917156 | 0.87 | GLA (0.34) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL5839660 | 0.86 | MGLL (0.33) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL11267463 | 0.85 | KMT2A (0.34) | KMT2AATMMGLLCA2LMNA | |
| SCHEMBL16310469 | 0.85 | KMT2A (0.37) | KMT2AATMMGLLALDH1A1ACE | |
| SCHEMBL19704975 | 0.85 | MGLL (0.35) | KMT2AATMMGLLALDH1A1SMN1; SMN2 | |
| SCHEMBL22198221 | 0.84 | KMT2A (0.36) | KMT2AATMMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | ORASURE TECHNOLOGIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | ORASURE TECHNOLOGIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11759528-B2 | Peg linker and ligand drug conjugate | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2023-09-19 | — | — | US | disclosed |
| WO-2023161038-A1 | SPONGES BASED ON COLLAGEN-LIKE PROTEINS | EVONIK OPERATIONS GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022137156-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Oncoarendi Therapeutics S.A. (PL) | 2022-06-30 | — | — | WO | disclosed |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | ORASURE TECHNOLIGIES, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| WO-2022118277-A1 | CARBONIC ANHYDRASE INHIBITORS SYNTHESIZED ON INTERCONNECTING LINKER CHAINS | VILNIUS UNIVERSITY (LT) | 2022-06-09 | — | — | WO | disclosed |
| WO-2021261712-A1 | HEMOGLOBIN DERIVATIVE CO-CONJUGATED WITH FATTY ACID-LINKED PEG AND ALKOXY PEG AS A BLOOD SUBSTITUTE | SUNBIO, INC. (KR) | 2021-12-30 | — | — | WO | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-0794788-A4 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORP (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-0918547-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0799050-A4 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0799050-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0759913-A1 | AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN AND SULFUR DONOR ATOM LIGANDS FOR IMAGING | NEORX CORPORATION (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996017618-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795239-B2 | Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy | DNTT, POLRMT, SLC29A1 | MMP1 918/4885MMP2 2152/4885MMP3 1595/4885 |
| US-11826485-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | MMP1 216/4885MMP2 1229/4885MMP3 2237/4885 |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | MMP1 4627/4885MMP2 4846/4885MMP3 4308/4885 |
| US-20220196641-A1 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR METABOLITES | DNTT, SLC29A1, SAMHD1 | MMP1 1653/4885MMP2 3156/4885MMP3 1848/4885 |
| US-11759528-B2 | Peg linker and ligand drug conjugate | EGFR, MPEG1, ERBB2 | MMP1 1978/4885MMP2 1609/4885MMP3 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.